

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657



VLL\SE\067\2025-26
Date: 03.11.2025

B S E Limited, P J Towers, Dalal Street, Mumbai - 400001. Scrip Code : 524394	National Stock Exchange of India Limited, "Exchange Plaza", Bandra, Kurla Complex, Bandra (E), Mumbai – 400051. Trading Symbol: VIMTALABS
--	--

Dear Sir/Madam,

Sub – Press Release – Unaudited Financial Results – 30th September 2025.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find attached the press release regarding the announcement of the unaudited Financial Results for the 2nd Quarter and Half year ended 30th September 2025.

This is for your information and records.

Thanking you,

For VIMTA LABS LIMITED

Sujani Vasireddi
Company Secretary



Encl: as above.

Vimta Labs Limited Reports Q2 & H1 FY26 Results

Highest Ever Quarterly Revenue reported at Rs. 1,045 Mn, up 22.3% YoY
EBITDA margins at 35.3%; PAT margin at 19.1%

Hyderabad, November 03, 2025: Vimta Labs Limited (VIMTA) (BSE: 524394, NSE: VIMTALABS), India's leading Contract Research and Testing Organisation, has announced its financial results for the quarter and half year ended September 30, 2025.

Financial Results – Q2 & H1 FY26:

Particulars (Rs. Mn)	Q2 FY26	Q1 FY26	QoQ (%)	Q2 FY25	YoY (%)	H1 FY26	H1 FY25	YoY (%)
Total Income	1,045	993	5.2%	854	22.3%	2,038	1,610	26.6%
EBITDA (including other income)	369	354	4.2%	306	20.6%	723	572	26.4%
EBITDA Margin	35.3%	35.7%		35.8%		35.5%	35.5%	
PAT (continued operations)	199	189	5.3%	170	17.1%	388	309	25.6%
PAT Margin	19.1%	19.0%		19.9%		19.0%	19.2%	
Basic EPS	4.5	4.3	4.6%	3.8	18.4%	8.7	7.0	24.3%

Note: Vimta Labs sold its Diagnostic and Pathological services business to Thyrocare Technologies, as announced on August 30, 2024, with the transfer completed on October 11, 2024. Previous period figures for P&L have been regrouped to ensure comparability with the current period

Commenting on results, Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited, said:
"I am delighted to share that Vimta Labs had a successful quarter with highest ever revenue reported i.e. ~Rs. 104 Cr. This growth was a result of our Pharmaceutical research and testing services and Food testing services performing well, while experiencing stable performance from other services provided by us.

We would like to mention that our company had a successful WHO audit for Clinical Research during the quarter, reflecting our commitment to maintain the highest global standards of quality and compliance.

With a focus on maintaining excellence in quality, innovation, and competence, we continue to strengthen our capabilities and deliver sustainable value to all stakeholders."

Key Result Highlights for the Q2 & H1 FY26:

Q2 FY26

- ✓ Total Income for Q2 FY26 was at Rs. 1,045 Mn
- ✓ EBITDA for Q2 FY26 was Rs. 369 Mn; EBITDA margin was at 35.3%
- ✓ PBT for Q2 FY26 was at Rs. 263 Mn
- ✓ Q2 FY26 PAT was at Rs. 199 Mn; PAT margin was at 19.1%
- ✓ Basic EPS in Q2 FY26 was Rs. 4.5

H1 FY26

- ✓ Total Income for H1 FY26 was at Rs. 2,038 Mn
- ✓ EBITDA for H1 FY26 was Rs. 723 Mn; EBITDA margin was at 35.5%

PRESS RELEASE

For Immediate dissemination



- ✓ PBT for H1 FY26 was at Rs. 515 Mn
- ✓ H1 FY26 PAT was at Rs. 388 Mn; PAT margin was at 19.0%
- ✓ Basic EPS in H1 FY26 was Rs. 8.7

Note:

Vimta Labs sold its Diagnostic and Pathological services business to Thyrocare Technologies, as announced on August 30, 2024, with the transfer completed on October 11, 2024. Previous period figures for P&L have been regrouped to ensure comparability with the current period

ABOUT VIMTA LABS LIMITED:

Founded in 1984 with headquarters in Hyderabad, India, VIMTA LABS LTD., is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides environmental assessments and testing services.

CAUTIONARY STATEMENT:

This press release may contain certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Vimta Labs Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations at Vimta Labs Siva Kambhampati (Chief Financial Officer) Siva.Kambhampati@Vimta.com	Registered Office Plot Number 142, IDA Phase 2, Cherlapally, Hyderabad Telangana, India. 500051 CIN: L24110TG1990PLC011977 ISIN: INE579C01029 NSE Code: VIMTALABS BSE CODE: 524394 Website: www.vimta.com
Ernst & Young Siddesh Chawan Siddesh.Chawan@in.ey.com Advait Bhadekar Advait.bhadekar@in.ey.com	